Answers are grounded in this paper and cite their sources.
Estimating target populations for orphan drugs is challenging because epidemiological evidence is limited and heterogeneous. We examined data sources used in German health technology assessment (HTA), temporal trends, and differences between oncology and non-oncology procedures. We retrospectively analyzed German orphan drug HTA procedures completed from 2012 to 2025. Public manufacturer dossiers, IQWiG assessments, and Federal Joint Committee resolutions were reviewed, and procedures classified by the primary epidemiological source were used to derive the final statutory health insurance target population estimate. Among 162 procedures, Literature was the most frequent primary source (43.2%), followed by Literature and Registry data (17.3%), Routine data (16.0%), and Registry data (15.4%). Use of Routine data increased from 3.7% in 2012–2015 to 25.0% in 2021–2025. Source distributions differed significantly between oncology and non-oncology procedures (χ2(3) = 36.8, p < 0.001; Cramér’s V = 0.477), with greater use of registry-based sources in oncology. An exact Monte Carlo analysis of the unpooled table confirmed the association (p < 0.0001). Epidemiological evidence sources were heterogeneous, while use of Routine data increased substantially over time. Stronger registries, coding systems, and responsible secondary use of healthcare data may improve future rare disease target population estimates.
No takes yet. Share an insight, caveat, or question.
Roll et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: